|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 781.60 USD | +2.86% |
|
-1.16% | +1.26% |
| Capitalization | 80.21B 69.19B 62.48B 59.88B 109B 7,389B 114B 738B 296B 3,535B 301B 295B 12,685B | P/E ratio 2026 * |
19.8x | P/E ratio 2027 * | 16.7x |
|---|---|---|---|---|---|
| Enterprise value | 71.38B 61.57B 55.6B 53.29B 96.85B 6,576B 101B 656B 263B 3,146B 268B 262B 11,289B | EV / Sales 2026 * |
4.57x | EV / Sales 2027 * | 3.98x |
| Free-Float |
77.36% | Yield 2026 * |
0.5% | Yield 2027 * | 0.58% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | +2.86% | ||
| 1 week | -1.16% | ||
| Current month | -0.01% | ||
| 1 month | +0.17% | ||
| 3 months | +12.85% | ||
| 6 months | +40.44% | ||
| Current year | +1.26% |
| 1 week | 746.66 |  | 791.6 |
| 1 month | 745.07 | | 815 |
| Current year | 718.38 | | 821.11 |
| 1 year | 476.49 | | 821.11 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 451.6 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 31/12/2000 | |
| Chief Executive Officer | 73 | 07/01/1988 | |
| Director of Finance/CFO | 55 | 04/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 08/06/2023 | |
Michael Brown
BRD | Director/Board Member | 85 | 31/05/1991 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 31/05/1991 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.86% | -1.16% | +10.47% | +5.09% | 80.21B | |
| +2.30% | +3.64% | +54.72% | +226.73% | 56.58B | |
| -3.95% | +57.90% | +57.90% | +57.90% | 49.5B | |
| +2.98% | -0.47% | -43.40% | -49.46% | 48.23B | |
| +1.82% | +0.10% | +25.18% | -27.32% | 27.63B | |
| +6.13% | +5.48% | +56.53% | -59.42% | 22.01B | |
| +1.21% | -2.94% | +37.17% | +33.27% | 19.32B | |
| +4.95% | +7.18% | +120.00% | +120.85% | 18.14B | |
| +3.19% | +1.36% | +30.51% | +61.84% | 14.12B | |
| -1.74% | -10.06% | -0.54% | +900.00% | 13.27B | |
| Average | +1.97% | -1.40% | +34.85% | +126.95% | 34.9B | |
| Weighted average by Cap. | +1.79% | -1.32% | +28.56% | +78.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15.63B 13.48B 12.17B 11.67B 21.21B 1,440B 22.17B 144B 57.64B 689B 58.67B 57.41B 2,472B | 17.21B 14.85B 13.41B 12.85B 23.35B 1,586B 24.41B 158B 63.47B 758B 64.61B 63.22B 2,722B |
| Net income | 4.4B 3.79B 3.43B 3.28B 5.97B 405B 6.24B 40.44B 16.22B 194B 16.51B 16.15B 695B | 5.22B 4.51B 4.07B 3.9B 7.09B 481B 7.41B 48.04B 19.26B 230B 19.61B 19.19B 826B |
| Net Debt | -8.83B -7.61B -6.87B -6.59B -11.97B -813B -12.52B -81.16B -32.55B -389B -33.13B -32.42B -1,396B | -11.65B -10.05B -9.07B -8.69B -15.8B -1,073B -16.52B -107B -42.95B -513B -43.72B -42.78B -1,842B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/03/26 | 781.60 $ | +2.86% | 697,070 |
| 06/03/26 | 759.86 $ | -0.66% | 561,908 |
| 05/03/26 | 764.93 $ | -2.87% | 657,525 |
| 04/03/26 | 787.50 $ | +2.72% | 641,608 |
| 03/03/26 | 766.66 $ | -3.05% | 637,256 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition